Institutions / Rosalind Advisors, Inc.
Rosalind Advisors, Inc.
CIK 1622627 · Institution · as of Dec 31, 2025
Portfolio value
$274.46M
Positions
29
As of
Dec 31, 2025
Top holdings
Dec 31, 2025View all 29 →
| Company | Value | % of portfolio |
|---|---|---|
| Delcath Systems, Inc. | $33.00M | 12.0% |
| Savara IncSVRA | $20.52M | 7.5% |
| Fennec Pharmaceuticals Inc. | $20.12M | 7.3% |
| Xeris Biopharma Holdings, Inc. | $16.58M | 6.0% |
| Viridian Therapeutics, Inc. | $14.00M | 5.1% |
| Mediwound Ltd | $13.83M | 5.0% |
| Verastem, Inc. | $13.81M | 5.0% |
| Replimune Group, Inc. | $13.71M | 5.0% |
| Atyr Pharma Inc | $13.60M | 5.0% |
| Cybin Inc. | $13.56M | 4.9% |
| EyePoint, Inc. | $12.61M | 4.6% |
| CG Oncology, Inc. | $12.46M | 4.5% |
| Cytokinetics Inc | $12.39M | 4.5% |
| X4 Pharmaceuticals, Inc | $10.42M | 3.8% |
| Mind Medicine Mindmed Inc | $10.04M | 3.7% |
| Profound Medical Corp | $8.41M | 3.1% |
| InspireMD, Inc.NSPR | $6.95M | 2.5% |
| Ocular Therapeutix, Inc | $4.86M | 1.8% |
| Arrivent Biopharma IncAVBP | $4.34M | 1.6% |
| Talphera, Inc. | $4.08M | 1.5% |
| Myomo, Inc.MYO | $3.49M | 1.3% |
| Polypid Ltd | $3.02M | 1.1% |
| OnKure Therapeutics, Inc. | $2.12M | 0.8% |
| Regentis Biomaterials Ltd | $1.70M | 0.6% |
| Trevi Therapeutics, Inc. | $1.25M | 0.5% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.